Grifols Yönetim

Yönetim kriter kontrolleri 2/4

Grifols CEO'su Nacho Abia Buenache, Apr2024 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.014% doğrudan sahiptir ve bu hisselerin değeri € 942.54K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.8 yıl ve 7 yıldır.

Anahtar bilgiler

Nacho Abia Buenache

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	0.01%
Yönetim ortalama görev süresi	6.8yrs
Yönetim Kurulu ortalama görev süresi	7yrs

Son yönetim güncellemeleri

Recent updates

CEO

Nacho Abia Buenache (56 yo)

less than a year

Görev süresi

Mr. Jose Ignacio Abia Buenache, also known as Nacho, serves as Chief Executive Officer of Grifols, S.A. from April 1, 2024 and has been its Director since February 26, 2024. Mr. Abia Buenache had been Chie...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jose Ignacio Abia Buenache	CEO & Director	less than a year	Veri yok	0.014% € 942.5k
Alfredo Guerra	CFO & VP	17.8yrs	Veri yok	Veri yok
Lluis Gomez	Senior Vice President of Strategy & COO Office	no data	Veri yok	Veri yok
Nuria Lapeña	VP of Corporate Treasury	no data	Veri yok	Veri yok
David Bell	Chief Corporate Development	21.8yrs	Veri yok	0.0029% € 202.9k
Maria Teresa-Rioné Llano	Chief Communications Officer	6.8yrs	Veri yok	0.00078% € 53.8k
Camille Alpi	Chief Human Resources & Talent Officer	less than a year	Veri yok	Veri yok
Vicente Blanquer Torre	Chief Quality Officer	31.8yrs	Veri yok	Veri yok
Sergio Adell	President of Commercial Tech Support	5.8yrs	Veri yok	Veri yok
Víctor Grifols Deu	Executive Director	no data	€1.04m	0.016% € 1.1m
Miguel Montblanch	President of Commercial Operations Support	12.8yrs	Veri yok	Veri yok
Daniel Coit	Chief Industrial Services Officer	5.8yrs	Veri yok	Veri yok

6.8yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim: G0F 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jose Ignacio Abia Buenache	CEO & Director	less than a year	Veri yok	0.014% € 942.5k
Víctor Grifols Deu	Executive Director	8.5yrs	€1.04m	0.016% € 1.1m
Iñigo Mardones	Independent Director	9.5yrs	€150.00k	Veri yok
Thomas Glanzmann	Non-Executive Chairman	18.6yrs	€1.90m	0.029% € 2.0m
Juan Twose Roura	Member of the Advisory Committee	9.8yrs	€380.00k	Veri yok
Raimon Grifols Roura	Vice-Chairman	9.5yrs	€1.04m	0.0060% € 417.4k
Tomas Daga Gelabert	Independent External Director	24.6yrs	Veri yok	0.045% € 3.1m
Albert Coma-Cros	Proprietary Director	less than a year	Veri yok	0.0097% € 670.0k
Enriqueta Font	Independent Director	5.5yrs	€125.00k	Veri yok
Montserrat Abellana	Lead Independent Director	2.4yrs	€63.00k	Veri yok
Susana Gonzalez Rodriguez	Independent Director	2.4yrs	€63.00k	Veri yok
Anne-Catherine Berner	Independent Director	less than a year	Veri yok	Veri yok

7.0yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: G0F 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7 yıldır).

Grifols Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Recent updates

Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

Grifols Receives Fda Approval to Treat Surgical Bleeding in Pediatric Patients with Its Fibrin Sealant Solution

Brookfield Reportedly Courts Sovereign Funds to Join Grifols Takeover Bid

Grifols, S.A. Reaffirms Earnings Guidance for the Full Year 2024

Grifols Receives Expanded XEMBIFY (Immune Globulin Subcutaneous Human-Klhw) Label in U.S., Strengthening Its Ig Portfolio for Patients

Grifols Family Holders, Brookfield to Evaluate Possible Joint Takeover Bid

Haiyingkang (Qingdao) Medical Technology Co., Ltd. completed the acquisition of 20% equity stake in Shanghai RAAS Blood Products Co., Ltd. (SZSE:002252) from Grifols, S.A. (BME:GRF).

Grifols, S.A. to Report Q2, 2024 Results on Jul 30, 2024

Grifols, S.A., Annual General Meeting, Jun 13, 2024

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Launches Alphaid™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic Copd

Grifols, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023

Grifols, S.A. to Report Q3, 2022 Results on Nov 08, 2022

Grifols Receives FDA Clearance for AlphaID(TM) At Home, the First Free Service for U.S. Consumers to Determine Their Risk for Alpha-1

Grifols Announces Management Changes

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Grifols, S.A. to Report First Half, 2022 Results on Jul 28, 2022

Grifols, S.A., Annual General Meeting, Jun 09, 2022

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş